Emmaus Life Sciences, Inc. EMMAW OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

20/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Emmaus Life Sciences, Inc. (EMMAW) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 19/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

20/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

25/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

MOAT

50/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — EMMAW

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.33

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.12

Book Value / Share$0.00

Revenue / Share$0.19

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2014	$-0.05	$135.1K	$-2.66M	-1968.9%
2015	$-0.07	$100.1K	$-3.39M	-3382.6%
2016	$-0.12	$85.1K	$-5.94M	-6981.2%
2017	$-0.14	$128.5K	$-7.11M	-5535.4%
2018	$-0.21	$1.32M	$-10.33M	-785.2%
2019	$-1.11	$22.75M	$-54.84M	-241%
2020	$0.02	$23.17M	$1.1M	4.7%
2021	$-0.32	$20.61M	$-15.95M	-77.4%
2024	$-0.10	$16.65M	$-6.45M	-38.7%
2025	$-0.12	$12.45M	$-7.49M	-60.2%